China Issues Guidance To Promote Domestic Innovation And Facilitate Industry Consolidation
This article was originally published in PharmAsia News
SHANGHAI - Before the release of a new five-year plan, China's Ministry of Industry and Information Technology, the Ministry of Health and the State FDA jointly released new guidance Nov. 9 to expedite restructuring China's healthcare industry, a signal of the government's efforts to promote innovation and industry consolidation
You may also be interested in...
SHANGHAI - China's State FDA recently issued a note to provincial FDA offices to require pharma companies and active pharmaceutical ingredient producers to file a Common Technical Document when they submit manufacturing applications as an effort to improve drug quality and research and development work in China
SHANGHAI - The National Development and Reform Commission, China's leading economic regulatory body, is revising a drug price control plan that was issued in June for public feedback after receiving industry-led objections to some proposals
SHANGHAI - The National Development and Reform Commission, China's powerful economic regulatory body, is collecting feedback from industry for a new drug pricing guideline, which details new rules for setting drug prices in China's changing healthcare system